ATE396186T1 - Heteroarylsubstituierte tetrazolmodulatoren des metabotropischen glutamatrezeptors-5 - Google Patents

Heteroarylsubstituierte tetrazolmodulatoren des metabotropischen glutamatrezeptors-5

Info

Publication number
ATE396186T1
ATE396186T1 AT02776076T AT02776076T ATE396186T1 AT E396186 T1 ATE396186 T1 AT E396186T1 AT 02776076 T AT02776076 T AT 02776076T AT 02776076 T AT02776076 T AT 02776076T AT E396186 T1 ATE396186 T1 AT E396186T1
Authority
AT
Austria
Prior art keywords
heteroaryl
glutama
metabotropic
modulators
receptor
Prior art date
Application number
AT02776076T
Other languages
English (en)
Inventor
Nicholas Cosford
Jeffrey Roppe
Chixu Chen
Nicholas Smith
Thomas Reger
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of ATE396186T1 publication Critical patent/ATE396186T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
AT02776076T 2001-10-04 2002-10-01 Heteroarylsubstituierte tetrazolmodulatoren des metabotropischen glutamatrezeptors-5 ATE396186T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32713201P 2001-10-04 2001-10-04

Publications (1)

Publication Number Publication Date
ATE396186T1 true ATE396186T1 (de) 2008-06-15

Family

ID=23275282

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02776076T ATE396186T1 (de) 2001-10-04 2002-10-01 Heteroarylsubstituierte tetrazolmodulatoren des metabotropischen glutamatrezeptors-5

Country Status (8)

Country Link
US (1) US7253190B2 (de)
EP (1) EP1434773B1 (de)
JP (1) JP4303109B2 (de)
AT (1) ATE396186T1 (de)
AU (1) AU2002341921B2 (de)
CA (1) CA2462289C (de)
DE (1) DE60226756D1 (de)
WO (1) WO2003029210A2 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2295441T3 (es) * 2001-12-18 2008-04-16 MERCK & CO., INC. Moduladores de pirazol heteroaril sustituido de receptor 5 metabotropico de glutamato.
ATE486600T1 (de) * 2002-03-12 2010-11-15 Merck Sharp & Dohme Di-aryl-substituierte tetrazol-modulatoren des metabotropen glutamat-rezeptors-5
WO2004014871A1 (en) 2002-08-08 2004-02-19 Amgen Inc. Vanilloid receptor ligands and their use in treatments
WO2004018463A2 (en) * 2002-08-23 2004-03-04 Rigel Pharmaceuticals, Inc. Pyridyl substituted heterocycles useful for treating or preventing hcv infection
DE60306193T2 (de) 2002-11-27 2006-10-12 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield 1,2,3-triazolamid-derivate als cytokininhibitoren
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1613614A2 (de) * 2003-04-03 2006-01-11 Merck & Co., Inc. Diarylsubstituierte pyrazolmodulatoren des metabotropen glutamatrezeptors-5
WO2004087653A2 (en) * 2003-04-03 2004-10-14 Merck & Co., Inc. 4-ring imidazole derivatives as modulators of metabotropic glutamate receptor-5
WO2004099165A2 (en) 2003-05-02 2004-11-18 Rigel Pharmaceuticals, Inc. Heterocyclic compounds and hydro isomers thereof
US7531529B2 (en) * 2003-06-05 2009-05-12 Roche Palo Alto Llc Imidazole derivatives
CA2537141A1 (en) * 2003-09-02 2005-03-10 Merck And Co., Inc. Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5
US7410979B2 (en) 2003-11-19 2008-08-12 Rigel Pharmaceuticals, Inc. Synergistically effective combinations of dihaloacetamide compounds and interferon or ribavirin against HCV infections
RU2006118021A (ru) * 2003-12-19 2007-12-10 АстраЗнека АБ (SE) Замещенные пиридин-2-ил-тетразолы (варианты), фармацевтическая композиция, лекарственное средство, способ лечения расстройств с их использованием, способ ингибирования активации метаботропных глютаматных рецепторов -5 и способ получения пиридилпроизводных
MY139645A (en) 2004-02-11 2009-10-30 Amgen Inc Vanilloid receptor ligands and their use in treatments
US7534798B2 (en) 2004-02-11 2009-05-19 Amgen Inc. Vanilloid receptor ligands and their use in treatments
AU2005215379A1 (en) * 2004-02-12 2005-09-01 Merck & Co., Inc. Bipyridyl amides as modulators of metabotropic glutamate receptor-5
AU2005214375A1 (en) * 2004-02-18 2005-09-01 Astrazeneca Ab Triazole compounds and their use as metabotropic glutamate receptor antagonists
US20070197549A1 (en) * 2004-02-18 2007-08-23 Astrazeneca Ab Tetrazole compounds and their use as metabotropic glutamate receptor antagonists
EP1716143A1 (de) * 2004-02-18 2006-11-02 AstraZeneca AB Polyheterocyclische verbindungen und deren verwendung als antagonisten des metabotropen glutamatrezeptors
TW200538108A (en) 2004-02-19 2005-12-01 Astrazeneca Ab Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists
US7514434B2 (en) 2004-02-23 2009-04-07 Rigel Pharmaceuticals, Inc. Heterocyclic compounds having an oxadiazole moiety and hydro isomers thereof
EP2305352A1 (de) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-Reduktaseinhibitoren zur Behandlung von Stoffwechsel- und anthropometrischen Störungen
JP4690395B2 (ja) 2004-06-01 2011-06-01 エフ.ホフマン−ラ ロシュ アーゲー mGlu5レセプターアンタゴニストとしてのピリジン−4−エチニル−イミダゾール及びピラゾール
EP1809620B1 (de) * 2004-11-04 2010-12-29 Addex Pharma SA Neuartige tetrazolderivate als positive allosterische modulatoren von metabotropen glutamatrezeptoren
GB0510143D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
JP2008523043A (ja) * 2004-12-08 2008-07-03 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー テトラゾリル−メチレンアミノ酸誘導体
WO2006089311A1 (en) 2005-02-15 2006-08-24 Amgen Inc. Vanilloid receptor ligands and their use in treatments
JP2008540425A (ja) 2005-05-02 2008-11-20 ライジェル ファーマシューティカルズ, インコーポレイテッド 代謝可能部分を含む複素環式抗ウイルス性化合物およびその使用
GB0510141D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
HUP0500921A2 (en) * 2005-10-05 2007-07-30 Richter Gedeon Nyrt Tetrazole derivatives, process for their preparation and their use
US7951824B2 (en) * 2006-02-17 2011-05-31 Hoffman-La Roche Inc. 4-aryl-pyridine-2-carboxyamide derivatives
DK2848610T3 (da) * 2006-11-15 2017-11-06 Ym Biosciences Australia Pty Hæmmere af kinaseaktivitet
CA2669915C (en) 2006-11-17 2012-02-07 Pfizer Inc. Substituted bicyclocarboxyamide compounds
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US7879802B2 (en) 2007-06-04 2011-02-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EA201070143A1 (ru) * 2007-07-13 2010-08-30 Аддекс Фарма С.А. Новые гетероароматические производные и их использование в качестве положительных аллостерических модуляторов метаботропных глутаматных рецепторов
MX2010002266A (es) * 2007-08-30 2010-03-25 Takeda Pharmaceutical Derivados de pirazol sustituidos.
AR068921A1 (es) 2007-10-19 2009-12-16 Astrazeneca Ab Derivados heterociclicos de tetrazol y 1,2-4 triazoles, composiciones farmaceuticas que los contienen y usos de los mismos para tratar desordenes neurologicos, gastrointestinales y del dolor,entre otros.
WO2009054790A1 (en) * 2007-10-26 2009-04-30 Astrazeneca Ab Amide linked heteroaromatic derivatives as modulators of mglur5
EP3239170B1 (de) 2008-06-04 2019-03-20 Synergy Pharmaceuticals Inc. Für die behandlung von gastrointestinalen erkrankungen, entzündungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase
EP3241839B1 (de) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Zur behandlung von erkrankungen des magen-darm-trakts, entzündlichen erkrankungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase
KR20110092266A (ko) 2008-08-04 2011-08-17 씨에이치디아이 파운데이션, 인코포레이티드 소정 키누레닌-3-모노옥시게나아제 억제제, 약학적 조성물, 및 그의 사용 방법
US20120095056A1 (en) * 2009-03-19 2012-04-19 Neurosearch A/S 2,5-disubstituted tetrazole derivatives and their use as nicotinic acetylcholine receptor modulators
WO2011073297A1 (en) 2009-12-18 2011-06-23 Neurosearch A/S Tetrazole derivatives as nicotinic acetylcholine receptor moudlators
WO2011073298A1 (en) * 2009-12-18 2011-06-23 Neurosearch A/S Tetrazole derivatives as nicotinic acetylcholine receptor modulators
HUE044447T2 (hu) 2010-09-02 2019-10-28 Monsanto Technology Llc Új készítmények és eljárások fonálféreg kártevõk irtására
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP2630133A1 (de) 2010-10-22 2013-08-28 Bayer Intellectual Property GmbH Neue heterocylische verbindungen als schädlingsbekämpfungsmittel
CN106518845B (zh) 2011-08-30 2019-09-13 Chdi基金会股份有限公司 犬尿氨酸-3-单加氧酶抑制剂、药物组合物及其使用方法
BR112014004845A2 (pt) 2011-08-30 2017-04-04 Chdi Foundation Inc pelo menos uma entidade química; pelo menos um composto; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada
KR101357395B1 (ko) * 2012-08-06 2014-02-05 영남대학교 산학협력단 신규한 테트라졸로 하이드라존 유도체 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학 조성물
EP2914587A1 (de) 2012-10-31 2015-09-09 Bayer CropScience AG Neue heterocylische verbindungen als schädlingsbekämpfungsmittel
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
AR095330A1 (es) 2013-03-15 2015-10-07 Monsanto Technology Llc Azoles n-,c-disustituidos y composiciones y métodos para controlar plagas de nematodos
JP6606491B2 (ja) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼcの超高純度アゴニスト、その作成および使用方法
SG11201700341PA (en) 2014-07-17 2017-02-27 Chdi Foundation Inc Methods and compositions for treating hiv-related disorders
CN112020500A (zh) 2017-12-22 2020-12-01 拉文纳制药公司 作为磷脂酰肌醇磷酸激酶抑制剂的氨基吡啶衍生物
CN108484452B (zh) * 2018-03-22 2020-10-27 东北师范大学 一种氟烷基磺酰腙的制备方法
AR122711A1 (es) 2020-06-25 2022-09-28 Alchemedicine Inc COMPUESTO HETEROCÍCLICO COMO INHIBIDOR DE CASEÍNA QUINASA 1d Y/O QUINASA 5 TIPO RECEPTOR DE ACTIVINA

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0412848B1 (de) * 1989-08-11 1995-01-18 Zeneca Limited Chinolin-Derivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
IE903911A1 (en) * 1989-11-20 1991-05-22 Ici Plc Diazine derivatives
WO1997003967A1 (en) * 1995-07-22 1997-02-06 Rhone-Poulenc Rorer Limited Substituted aromatic compounds and their pharmaceutical use
FR2743366B1 (fr) * 1996-01-10 1998-02-06 Rhone Poulenc Rorer Sa Derives de 5h,10h-imidazo(1,2-a)indeno(1,2-e)pyrazine-4-one, leur preparation, leurs intermediaires et les medicaments les contenant
DE19643037A1 (de) * 1996-10-18 1998-04-23 Boehringer Ingelheim Kg Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
JPH10195063A (ja) * 1996-10-21 1998-07-28 Dai Ichi Seiyaku Co Ltd エチニルチアゾール誘導体

Also Published As

Publication number Publication date
US20040186295A1 (en) 2004-09-23
EP1434773A2 (de) 2004-07-07
CA2462289C (en) 2010-02-23
JP4303109B2 (ja) 2009-07-29
JP2005508344A (ja) 2005-03-31
EP1434773B1 (de) 2008-05-21
WO2003029210A3 (en) 2003-11-20
AU2002341921B8 (en) 2003-04-14
DE60226756D1 (de) 2008-07-03
WO2003029210A2 (en) 2003-04-10
AU2002341921B2 (en) 2007-05-31
US7253190B2 (en) 2007-08-07
EP1434773A4 (de) 2005-01-12
CA2462289A1 (en) 2003-04-10

Similar Documents

Publication Publication Date Title
ATE396186T1 (de) Heteroarylsubstituierte tetrazolmodulatoren des metabotropischen glutamatrezeptors-5
WO2003053922A3 (en) Heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5
WO2003051833A3 (en) Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5
DE60131967D1 (de) Nr1h4-kern-rezeptor-bindende verbindungen
ATE374194T1 (de) Heteroarylsubstituierte triazolmodulatoren des metabotropen glutamatarezeptors 5
ATE493397T1 (de) Neuartige tetrazolderivate als positive allosterische modulatoren von metabotropen glutamatrezeptoren
ATE490253T1 (de) Synthese von 5-substituierten 7-azaindolen und 7- azaindolinen
NO20064032L (no) DPP-IV inhibitorer
MEP45308A (en) [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
DE50306845D1 (de) Disubstituierte thiazolylcarboxanilide und ihre verwendung als mikrobizide
DE602004017213D1 (de) Allosterische modulatoren von metabotropen glutamatrezeptoren
UA87856C2 (ru) Алкильные производные как модуляторы метаботропных рецепторов глутамата
ATE486600T1 (de) Di-aryl-substituierte tetrazol-modulatoren des metabotropen glutamat-rezeptors-5
CY1106969T1 (el) Αναστολεις dpp-iv
NO20063275L (no) Anvendelse av substituerte 2-aminotetraliner for forebyggende behandling av Parkinsons sykdom
DE60315323D1 (de) Piperidinderivate zur verwendung bei der behandlung von durch chemokins vermittelten leiden
WO2004024074A3 (en) Fused heterobicyclo substituted phenyl metabotropic glutamate-5 modulators
DE60237528D1 (de) Neue aminoazetidin-, aminopyrrolidin- und aminopiperidinderivative
DE50202504D1 (de) Neue 4-aminofuropyrimidine und ihre verwendung
MXPA05011962A (es) Oxiarenos substituidos.
ATE347555T1 (de) 6-aminomorphinanderivate, herstellungsverfahren dafür und deren verwendung
ATE411287T1 (de) Neue metallproteinaseinhibitoren
DE60221813D1 (de) Thiazolopyrimidinderivate und deren verwendung als antagonisten des cx3cr1 rezeptors
BRPI0416678A (pt) pirazolpirimidinas
DE60207104D1 (de) 2-amino-4-heteroarylethyl-thiazolinderivate und ihre verwendung als hemmstoffe der induzierbaren no-synthase

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties